Advancing C5AR1 Drug Development in 2026: How Humanized Mouse Models Support Next-Generation C5AR1 Antagonists
Complement C5a receptor 1 (C5AR1, also known as C5aR1 or CD88), a key G protein-coupled receptor (GPCR) in the complement system, has long served as the central regulatory node for neutrophil-driven inflammation. At the end of 2025, Biogen secured global exclusive rights to Vanqua Bio’s preclinical oral, peripherally directed C5AR1 antagonist in a deal worth up to $1.06 billion [1]. This bold move quickly drew widespread industry attention, underscoring Big Pharma’s sustained confidence in the C5AR1 target and its particular use in neutrophil-mediated conditions.
As we enter June 2026, with the publication of a series of clinical data, differentiation opportunities in the C5AR1 track have become increasingly evident. Avacopan (Tavneos®), the first approved oral C5AR1 antagonist, achieved a major breakthrough in steroid-sparing for ANCA-associated vasculitis (AAV). However, the liver injury warning issued by the FDA in March–April this year has poured cold water on the market[2]. This has also made subsequent developers more acutely aware that safety will be the core competitive edge for next-generation C5AR1 drugs.
At the same time, InflaRx’s Izicopan (INF904) delivered eye-catching research data in May this year: no CYP3A4 time-dependent inhibition, low-reactivity metabolites, and a significantly reduced risk of hepatotoxicity. Combined with positive results from its prior Phase 2a trial, Izicopan is viewed as the best-in-class candidate most likely to sidestep the “hepatotoxicity pitfall” [3]. Moreover, Biogen is currently advancing both Izastobart (an anti-C5AR1 monoclonal antibody) and its oral small-molecule program in parallel. This dual-pronged “small molecule + biologic” strategy further validates the strategic value of C5AR1 as the core target for neutrophil-driven inflammation.
1. C5AR1 Mechanism of Action: How the C5a Receptor Drives Neutrophil Inflammation and Tissue Damage
C5AR1 is a classic seven-transmembrane G protein-coupled receptor (GPCR) that is highly expressed on the surface of myeloid immune cells, including neutrophils, macrophages, and monocytes. Its ligand C5a is a potent anaphylatoxin generated upon activation of the complement system and is known as the “inflammation amplifier.” Upon binding to C5AR1, C5a rapidly triggers neutrophil chemotaxis, degranulation, reactive oxygen species (ROS) burst, and neutrophil extracellular trap (NETs) formation through the Gi/o protein signaling pathway. At the same time, it activates the NF-κB and MAPK pathways, leading to the release of large amounts of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, thereby amplifying vascular injury and tissue fibrosis [4].
This upstream “switch-like” property positions C5AR1 as an ideal target for precisely regulating excessive inflammation without broadly suppressing the immune system. The recent accumulation of high-resolution crystal structures and Cryo-EM data has also provided a solid structural foundation for the design of next-generation oral small-molecule drugs with high selectivity and high affinity.
2. Expanding C5AR1 Applications Beyond AAV: Unmet Needs in Hidradenitis Suppurativa, Lupus Nephritis, Neuroinflammation & Oncology
It is precisely because C5AR1 acts as the “core switch” for neutrophil-driven inflammation that its drug-development potential has long extended far beyond ANCA-associated vasculitis (AAV), becoming a new high-ground spanning multiple disease models. This pathway is now showing enormous potential in the following broader therapeutic areas:
- Skin diseases: hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU). Neutrophil infiltration is a major pathological feature[6-7];
- Kidney diseases: lupus nephritis, C3 glomerulopathy[8-9];
- Neuroinflammation: central nervous system lupus, glial cell activation in certain neurodegenerative diseases[10];
- Tumor microenvironment: C5AR1 promotes recruitment of immunosuppressive cells. Blocking it is expected to reshape the phenotype of tumor-associated macrophages and enhance the efficacy of existing immunotherapies [11].
These real-world industry moves collectively demonstrate that C5AR1 is a fully validated, mature target, and 2026 represents the golden window for clinical translation.
3. Cyagen huC5AR1 Humanized Mouse Model: Overcoming Species Differences for Reliable C5AR1 Preclinical Testing
Inflammatory diseases carry a heavy global burden, driving strong patient demand for safe, effective, and convenient therapies. However, C5AR1 drug development faces a significant challenge.
For the C5AR1 target, human C5AR1 and murine C5AR1 exhibit significant differences in protein sequence and three-dimensional conformation. As a result, many highly humanized antibodies or small-molecule compounds that show excellent performance in vitro are difficult to evaluate accurately for affinity, pharmacokinetics/pharmacodynamics (PK/PD), true in vivo efficacy, and most critically, safety data in wild-type mice. This has become a major bottleneck for IND filing and clinical translation. Therefore, under the dual pressures of hepatotoxicity concerns and intense competition, how can differentiated pipelines be advanced faster and more safely?
To help industry partners overcome this pain point, Cyagen has launched the huC5AR1 humanized mouse model (Product No.: C001714). This model can be used for research on various inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), neuroinflammation associated with Alzheimer's disease (AD), and the pathogenesis of certain tumors. Representative validation data are provided below. For detailed data, please refer to the product manual.
- Myeloid cells in bone marrow and spleen tissues of huC5AR1 mice express human C5AR1 protein at physiologically relevant levels.
- The overall levels of white blood cells, red blood cells, and platelet-related parameters in huC5AR1 mice are comparable to those in wild-type (WT) control mice. All tested indicators fall within normal physiological ranges, and no significant genotype-related differences were observed.
In this critical window as companies such as Biogen and InflaRx accelerate their strategic positioning in the C5AR1 space, Cyagen’s huC5AR1 humanized mouse model (Product No.: C001714) serves as the key enabling tool to overcome human-mouse species difference challenges and to drive the development of differentiated C5AR1 therapeutics. The path to conquering neutrophil-driven inflammation has now been opened. Explore Cyagen’s humanized mouse model and discover how it can accelerate your next-generation therapeutics.
Reference
[1] Biogen. (2025, October 24). Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio [Web] . GlobeNewswire.
[2] U.S. Food and Drug Administration. (2026, March 31). FDA identifies cases of serious liver injury in patients taking Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. U.S. Food and Drug Administration.
[3] InflaRx. (2026, May 11). InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes. InflaRx.
[4] Xu B, Zhou Z, Xiao Y, Liu Q, Xiao T, Lv Z, Wang H. The Pleiotropic Effect of Complement C5a-C5aR1 Pathway in Diseases: From Immune Regulation to Targeted Therapy. Int J Mol Sci. 2025 Dec 3;26(23):11693.
[5] Trambas IA, Coughlan MT, Tan SM. Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease. Int J Mol Sci. 2023 May 15;24(10):8758.
[6] van Straalen KR, Dudink K, Aarts P, van der Zee HH, van den Bosch TPP, Giang J, Prens EP, Damman J. Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander? Front Immunol. 2022 Sep 21;13:953674.
[7] Yan S, Chen W, Wen S, Zhu W, Guo A, Chen X, Zhang C, Chen M, Zhang J, Su J, Zhao Y, He Y, Liu Z, Zhou H, Zeng W, Li J, Chen X. Influence of component 5a receptor 1 (C5AR1) -1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria. J Dermatol Sci. 2014 Dec;76(3):240-5.
[8] Ye B, Chen B, Guo C, Xiong N, Huang Y, Li M, Lai Y, Li J, Zhou M, Wang S, Wang S, Yang N, Zhang H. C5a-C5aR1 axis controls mitochondrial fission to promote podocyte injury in lupus nephritis. Mol Ther. 2024 May 1;32(5):1540-1560.
[9] Gong XJ, Huang J, Shu Y, Wang M, Ji J, Yang L, Zhao MH, Cui Z. Complement C5a and C5a receptor 1 mediates glomerular damage in focal segmental glomerulosclerosis. Clin Immunol. 2025 Apr;273:110459.
[10] Schartz ND, Liang HY, Carvalho K, Chu SH, Mendoza-Arvilla A, Petrisko TJ, Gomez-Arboledas A, Mortazavi A, Tenner AJ. C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer's disease mouse model. Nat Commun. 2024 Aug 15;15(1):7028.
[11] Beach C, MacLean D, Majorova D, Melemenidis S, Nambiar DK, Kim RK, Valbuena GN, Guglietta S, Krieg C, Darvish-Damavandi M, Suwa T, Easton A, Hillson LV, McCulloch AK, McMahon RK, Pennel K, Edwards J, O'Cathail SM, Roxburgh CS, Domingo E, Moon EJ, Jiang D, Jiang Y, Zhang Q, Koong AC, Woodruff TM, Graves EE, Maughan T, Buczacki SJ, Stucki M, Le QT, Leedham SJ, Giaccia AJ, Olcina MM. Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest. 2023 Dec 1;133(23):e168277.
